NCT00060515终止1 期
An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 12
研究概览
简要总结
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Clinical Study of SM3321 With Solid TumorsLocally Advanced or Metastatic Solid TumorsNCT06087770Beijing StarMab Biomed Technology Ltd7
已完成
1 期
MGD009/MGA012 Combination in Relapsed/Refractory CancerAdvanced Solid TumorsNCT03406949MacroGenics25
撤回
1 期
Safety and Immunogenicity Study of GX-70 in TB PatientPulmonary TuberculosesHigh Risk Factors for RelapseTreatment FailureNCT03159975Yonsei University
已完成
1 期
A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04338724CStone Pharmaceuticals6
已完成
1 期
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic RetinopathyDiabetic Macular EdemaDiabetic RetinopathyNCT00401115Santen Inc.50